Company: RGBP
Filing Date: 2025-05-16
Form Type: 10-Q
Source: 0001641172-25-011206
Chunk: 4

Company: Regen BioPharma Inc
Filing Date: 2025-05-16
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
,
revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions
required to be satisfied in order for that revenue to have been earned by the Company.

J. RESEARCH AND DEVELOPMENT COST

Research and development
(R& D) costs are expensed as incurred. R& D costs are related to the Company’s internally funded development of the Company’s
product developments and patents. The Company R& D costs were $0and $47,528for the quarters ended December 31, 2024 and 2023.

K. FAIR VALUE MEASUREMENT

The estimated fair values of financial instruments
reported in the consolidated financial statements have been determined using available market information and valuation methodologies,
as applicable. The fair value of cash due to its short maturity is classified as a Level1instrument within the fair value hierarchy.

Fair value is defined as the exchange price that would
be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or
liability in an orderly transaction between market participants on the measurement date. Entities are required to maximize the use of
observable inputs and minimize the use of unobservable inputs when measuring fair value based upon the following fair value hierarchy:

  Level 1 —      Quoted prices in active markets for identical assets or liabilities;                                                                                                                                  
  Level 2 —      Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be...  
  Level 3 —      Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.                                                       

As of December 31, 2024, the following
table represents the Company’s fair value hierarchy for items that are required to be measured at fair value on a recurring basis:

SCHEDULE
OF FAIR VALUE HIERARCHY MEASURED AT RECURRING BASIS

                                             Level 1      Level 2      Level 3  
  Investment Securities (Related Party)                                $17,733  
 ────────────────────────────────────────────────────────────────────────────────

As of September 30, 2024, the following
table represents the Company’s fair value hierarchy for items that are required to be measured at fair value on a recurring basis:

                                             Level 1      Level 2      Level 3  
  Investment Securities (